Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH9089 Injection in Patients Undergoing Abdominal Surgery
NCT07519109Phase 1Recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SYH9089 in postoperative pain (3 arms), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Adverse Event Profile at 14 days. Started Mar 2026; status: recruiting.
02
Drugs
SYH9089
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07519109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519109.